HAEMATO AG · ISIN: DE000A289VV1 · EQS - adhoc news

Termination of listing in the Open Market

Berlin, November 30, 2023: The Management Board of HAEMATO AG ("Company"; ISIN: DE000A289VV1/ Open Market / Basic Board) has decided today, November 30, 2023, with the approval of the Supervisory Board, to terminate the inclusion of the Company's shares in the Open Market (Basic Board) on the Frankfurt Stock Exchange pursuant to Section 30 of the General Terms and Conditions of Deutsche Börse AG for the Open Market on the Frankfurt Stock Exchange (so-called delisting). The Management Board of th...

XETR:HAEK Price indication powered by TradingView

About the publication

Corporate Insights - Short Sales, Director's Dealings, Sentiment Indicators - THE info hub for the informed investor

Smart tools for smart investors can be found in our Tools section

Corporate News HAEMATO AG

In this overview you can view company news in the chronological order of publication. The source information comes from EQS News, the leading European news distributor. The most recent news item is listed first.
Back to Corporate News Overview
This might be interesting for you as well
Analyst Ratings (33)
Directors Dealings (0)
Short Selling (DE) (0)
Short Selling (UK) (0)
30 November 2023 02:14PM
Termination of listing in the Open Market
DE000A289VV1
Berlin, November 30, 2023: The Management Board of HAEMATO AG ("Company"; ISIN: DE000A289VV1/ Open Market / Basic Board) has decided today, November 30, 2023, with the approval of the Supervisory Board, to terminate the inclusion of the Company's shares in the Open Market (Basic Board) on the Frankfurt Stock Exchange pursuant to Section 30 of the G...
HAEMATO AG
About the publication
16 November 2023 08:21AM
Sales increase of around 13% compared to the same period of the previous year, strong increase in EBIT margin and significant increase in
DE000A289VV1
HAEMATO AG publishes figures for the third quarter of 2023: Sales increase of around 13% compared to the same period of the previous year, strong increase in EBIT margin and significant increase in operating result:              In the first nine months of the 2023 financial year, preliminary IFRS consolidated sales rose by around 13% to EUR 212.2...
HAEMATO AG
About the publication
15 November 2023 07:42PM
Termination of the botulinum toxin project
DE000A289VV1
Berlin, 15. November 2023 – Due to new findings on changed market conditions, an updated validation of the profitability of the company's own botulinum toxin project was carried out.  After reviewing various options, the Executive Board decided today to terminate the cooperation with the Korean manufacturer Huons BioPharma and to discontinue the pr...
HAEMATO AG
About the publication
31 August 2023 09:00AM
HAEMATO AG publishes figures for the first half of 2023
DE000A289VV1
___________________________________________________________________________   HAEMATO AG publishes figures for the first half of 2023:   Increase in sales of more than 10% compared to the same period last year, further increase in EBIT margin and disproportionate increase in operating result                 In the first half of 2023, preliminar...
HAEMATO AG
About the publication
31 May 2023 04:34PM
HAEMATO AG with a strong start into the year 2023:   Revenue increase of over 25% compared to the same quarter of the previous year and disproportionate increase in the operating result
DE000A289VV1
HAEMATO AG with a strong start into the year 2023:  Revenue increase of over 25% compared to the same quarter of the previous year and disproportionate increase in the operating result                 In the first quarter of 2023, preliminary IFRS consolidated revenue increased by 25.3% to EUR 68.4 million compared to the same quarter of 2022 (EUR...
HAEMATO AG
About the publication
31 May 2023 04:34PM
  Revenue increase of over 25% compared to the same quarter of the previous year and disproportionate increase in the operating result
DE000A289VV1
HAEMATO AG with a strong start into the year 2023:  Revenue increase of over 25% compared to the same quarter of the previous year and disproportionate increase in the operating result                 In the first quarter of 2023, preliminary IFRS consolidated revenue increased by 25.3% to EUR 68.4 million compared to the same quarter of 2022 (EUR...
HAEMATO AG
About the publication
16 May 2023 05:40PM
Dividend of EUR 1.20
DE000A289VV1
Dividend of EUR 1.20  Berlin, May 16, 2023 - At today's balance sheet meeting, the annual financial statements 2022 of HAEMATO AG, which were issued with an unqualified audit certificate, were adopted. The preliminary figures were confirmed. The Executive Board and Supervisory Board will propose a dividend of EUR 1.20 per dividend-bearing share to...
HAEMATO AG
About the publication
16 May 2023 05:40PM
HAEMATO AG: Dividend of EUR 1.20
DE000A289VV1
Dividend of EUR 1.20  Berlin, May 16, 2023 - At today's balance sheet meeting, the annual financial statements 2022 of HAEMATO AG, which were issued with an unqualified audit certificate, were adopted. The preliminary figures were confirmed. The Executive Board and Supervisory Board will propose a dividend of EUR 1.20 per dividend-bearing share to...
HAEMATO AG
About the publication
13 April 2023 09:00AM
HAEMATO AG publishes preliminary figures for the 2022 financial year: Strong increase in net profit and operating cash flow
DE000A289VV1
HAEMATO AG publishes preliminary figures for the 2022 financial year: Strong increase in net profit and operating cash flow Strong annual result despite the sharp decline in special effects from the Corona test business: According to the preliminary IFRS financial statements, consolidated revenue fell by 12.9% to 248.1 million euros in the 2022 fi...
HAEMATO AG
About the publication
13 April 2023 09:00AM
Strong increase in net profit and operating cash flow
DE000A289VV1
HAEMATO AG publishes preliminary figures for the 2022 financial year: Strong increase in net profit and operating cash flow Strong annual result despite the sharp decline in special effects from the Corona test business: According to the preliminary IFRS financial statements, consolidated revenue fell by 12.9% to 248.1 million euros in the 2022 fi...
HAEMATO AG
About the publication
14 November 2022 09:00AM
publishes figures for the 3rd quarter 2022
DE000A289VV1
___________________________________________________________________________   HAEMATO AG publishes figures for the 3rd quarter 2022: Encouraging business development and increase in turnover compared to the previous quarter; confirmation of forecast for the full year 2022  In the third quarter of 2022, preliminary IFRS consolidated revenue rose ...
HAEMATO AG
About the publication
14 November 2022 09:00AM
HAEMATO AG: publishes figures for the 3rd quarter 2022
DE000A289VV1
___________________________________________________________________________   HAEMATO AG publishes figures for the 3rd quarter 2022: Encouraging business development and increase in turnover compared to the previous quarter; confirmation of forecast for the full year 2022  In the third quarter of 2022, preliminary IFRS consolidated revenue rose ...
HAEMATO AG
About the publication
17 August 2022 09:00AM
HAEMATO AG publishes figures for Q2 2022: increase in revenues and EBIT compared to the previous quarter; confirmation of guidance for the full year 2022
DE000A289VV1
___________________________________________________________________________   HAEMATO AG publishes figures for Q2 2022: increase in revenues and EBIT compared to the previous quarter; confirmation of guidance for the full year 2022 In the second quarter of 2022, preliminary IFRS consolidated revenues increased by around 22% to EUR 66.4 million c...
HAEMATO AG
About the publication
17 August 2022 09:00AM
increase in revenues and EBIT compared to the previous quarter; confirmation of guidance for the full year 2022
DE000A289VV1
___________________________________________________________________________   HAEMATO AG publishes figures for Q2 2022: increase in revenues and EBIT compared to the previous quarter; confirmation of guidance for the full year 2022 In the second quarter of 2022, preliminary IFRS consolidated revenues increased by around 22% to EUR 66.4 million c...
HAEMATO AG
About the publication
23 May 2022 08:30AM
HAEMATO AG publishes figures for Q1 2022: further improvement in EBIT margin and confirmation of guidance
DE000A289VV1
______________________________________________________________________________ HAEMATO AG publishes figures for Q1 2022: further improvement in EBIT margin and confirmation of guidance - Group turnover decreases to EUR 54.6 million (EUR 73.9 million in Q1-2021) due to product portfolio adjustment - Group EBITDA of EUR 2.3 million (previous year:...
HAEMATO AG
About the publication
03 May 2022 02:56PM
HAEMATO AG: Dividend of EUR 1.10
DE000A289VV1
______________________________________________________________________________ HAEMATO AG: Dividend of EUR 1.10 Berlin, May 3, 2022 - At today's balance sheet meeting, the annual financial statements 2021 of HAEMATO AG, which were issued with an unqualified audit certificate, were adopted. The preliminary figures were confirmed. The Executive Boa...
HAEMATO AG
About the publication
30 March 2022 10:15AM
HAEMATO AG - preliminary figures for the 2021 financial year: Renewed increase in sales and strong rise in earnings after disproportionate growth of the new Lifestyle and Aesthetics business unit
DE000A289VV1
______________________________________________________________________________ HAEMATO AG publishes preliminary figures for the 2021 financial year: Renewed increase in sales and strong rise in earnings after disproportionate growth of the new Lifestyle and Aesthetics business unit - HAEMATO remains on course for growth: according to preliminar...
HAEMATO AG
About the publication
28 March 2022 06:41PM
Expansion of the Executive Board of HAEMATO AG: Strengthening operational excellence
DE000A289VV1
______________________________________________________________________________ Expansion of the Executive Board of HAEMATO AG: Strengthening operational excellence Schönefeld, 28.03.2022 - In its meeting today, the Supervisory Board of HAEMATO AG appointed Mr. Attila Strauss to the Executive Board of HAEMATO AG with effect from 01.04.2022. Mr. A...
HAEMATO AG
About the publication
15 February 2022 02:45PM
HAEMATO adds a new generation test device to its portfolio
DE000A289VV1
DGAP-Media / 15.02.2022 / 14:45 Schönefeld, 15 February 2022 - HAEMATO PHARM GmbH ("HAEMATO"), a 100% subsidiary of HAEMATO AG (ISIN: DE000289VV1), is expanding its medical device portfolio in the fight against Corona virus. In addition to the already introduced Point-of-Care (PoC) PCR device, HAEMATO is now also marketing the Mini Dock, an ...
HAEMATO AG
About the publication
14 January 2022 02:45PM
HAEMATO distributes PCR point-of-care devices for effective containment of corona pandemic
DE000A289VV1
DGAP-Media / 14.01.2022 / 14:45 HAEMATO distributes PCR point-of-care devices for effective containment of corona pandemic Schönefeld, 13th January 2022 - With the current omicron wave, laboratories in Germany are facing a sharp increase in PCR testing. The evaluation capacities are pushing increasingly towards their limits, especially with...
HAEMATO AG
About the publication
18 November 2021 07:00AM
HAEMATO AG reports figures for the 3rd quarter of 2021: Further increase in revenue and earnings as well as confirmation of revenue and earnings expectations for 2021
DE000A289VV1
______________________________________________________________________________ HAEMATO AG reports figures for the 3rd quarter of 2021: Further increase in revenue and earnings as well as confirmation of revenue and earnings expectations for 2021 - HAEMATO continues to grow: consolidated revenue in the third quarter of 2021 increased by 9% year-ov...
HAEMATO AG
About the publication
25 October 2021 10:25AM
HAEMATO seeks marketing authorization and plans distribution of a botulinum toxin product under its own brand in Europe
DE000A289VV1
DGAP-Media / 25.10.2021 / 10:25 HAEMATO seeks marketing authorization and plans distribution of a botulinum toxin product under its own brand in Europe Seoul and Schönefeld, 25th October 2021 - HAEMATO PHARM GmbH ("HAEMATO"), a wholly owned subsidiary of HAEMATO AG (ISIN: DE000289VV1), is expanding its own portfolio with a botulinum toxin p...
HAEMATO AG
About the publication
25 October 2021 10:21AM
HAEMATO seeks marketing authorization and plans distribution of a botulinum toxin product under its own brand in Europe
DE000A289VV1
HAEMATO seeks marketing authorization and plans distribution of a botulinum toxin product under its own brand in Europe Seoul and Schönefeld, 25th October 2021 - HAEMATO PHARM GmbH ("HAEMATO"), a wholly owned subsidiary of HAEMATO AG (ISIN: DE000289VV1) is expanding its own portfolio with a botulinum toxin product from the pharmaceutical company H...
HAEMATO AG
About the publication
11 August 2021 05:08PM
HAEMATO AG announces preliminary figures for Q2 2021: Increase in Q2 revenue by 41% and EBIT by 596% compared to the same quarter last year.
DE000A289VV1
______________________________________________________________________________ HAEMATO AG announces preliminary figures for Q2 2021: Increase in Q2 revenue by 41% and EBIT by 596% compared to the same quarter last year. Increase in revenue and profit expectation for 2021   - HAEMATO continues to grow strongly: in the second quarter of 2021, pre...
HAEMATO AG
About the publication
31 May 2021 08:37AM
HAEMATO AG with strong start to the year: EBIT rises in Q1 by 350 % to EUR 2.4 million and revenues by 22 % to EUR 73.9 million.
DE000A289VV1
______________________________________________________________________________ Corporate News of HAEMATO AG: HAEMATO AG with strong start to the year: EBIT rises in Q1 by 350 % to EUR 2.4 million and revenues by 22 % to EUR 73.9 million. Berlin, 31.05.2021 - HAEMATO AG (ISIN: DE000289VV1), has continued its growth course in the first months of 2...
HAEMATO AG
About the publication
04 May 2021 03:10PM
HAEMATO AG proposes dividend payment
DE000A289VV1
Ad hoc of HAEMATO AG: HAEMATO AG proposes dividend payment The Supervisory Board of HAEMATO AG approved the Executive Board's proposal for the appropriation of profits at today's balance sheet meeting. The Executive Board and Supervisory Board will therefore propose a dividend of EUR 1.00 per dividend-bearing share at the Annual General Meeting ...
HAEMATO AG
About the publication
21 April 2021 10:40AM
According to the preliminary IFRS financial statements for the 2020 financial year, HAEMATO AG increased its revenue by 20.5 % to EUR 238.3 million and increased EBITDA by 74.8 % to EUR 3.3 million
DE000A289VV1
Corporate News of HAEMATO AG: According to the preliminary IFRS financial statements for the 2020 financial year, HAEMATO AG increased its revenue by 20.5 % to EUR 238.3 million and increased EBITDA by 74.8 % to EUR 3.3 million. In the 2020 financial year, HAEMATO AG, Schoenefeld (ISIN: DE000289VV1), achieved IFRS consolidated revenues of EUR 23...
HAEMATO AG
About the publication
29 March 2021 05:05PM
HAEMATO AG successfully completes capital increase
DE000A289VV1
Ad hoc of HAEMATO AG: HAEMATO AG successfully completes capital increase March 29, 2021 HAEMATO AG (ISIN: DE000A289VV1, WKN: A289VV) has successfully completed the capital increase which was announced on March 24, 2021. The capital increase was oversubscribed.. The Company increased its share capital by € 475,391.00 to € 5,229,307.00 by issuin...
HAEMATO AG
About the publication
15 December 2020 03:10PM
HAEMATO AG: HAEMATO AG acquires 'M1 Aesthetics GmbH' from M1 Kliniken AG - Contribution of the company within the scope of a capital increase in kind of HAEMATO AG
DE000A289VV1
Berlin, 15.12.2020 - M1 Kliniken AG and HAEMATO AG today signed a contract for the acquisition of all shares in M1 Aesthetics GmbH by HAEMATO AG. M1 Kliniken AG will contribute M1 Aesthetics GmbH to HAEMATO AG within the scope of a capital increase through contribution in kind. For this purpose, the Management Board of HAEMATO AG decided today with...
HAEMATO AG
About the publication
15 December 2020 03:00PM
HAEMATO AG: HAEMATO AG acquires 'M1 Aesthetics GmbH' from M1 Kliniken AG - Contribution of the company within the scope of a capital increase in kind of HAEMATO AG
DE000A289VV1
Berlin, 15.12.2020 - M1 Kliniken AG and HAEMATO AG today signed a contract for the acquisition of all shares in M1 Aesthetics GmbH by HAEMATO AG. M1 Kliniken AG will contribute M1 Aesthetics GmbH to HAEMATO AG within the scope of a capital increase through contribution in kind. For this purpose, the Management Board of HAEMATO AG decided today with...
HAEMATO AG
About the publication
30 November 2020 03:00PM
HAEMATO AG: Expansion of the board of directors: Strengthening the strategic and operative implementa-tion of the product business in the Haemato Group
DE000A289VV1
Schönefeld, 30.11.2020 - The supervisory board of HAEMATO AG has appointed Mr. Patrick Brenske to the board of directors of HAEMATO AG at its meeting today. With immediate effect Mr. Patrick Brenske will take over the responsibility for the product business as well as for purchasing and sales. Until 2015 Mr. Brenske worked for the HAEMATO Group f...
HAEMATO AG
About the publication
23 November 2020 04:15PM
HAEMATO AG: The sales of HAEMATO AG increased in the first nine months of 2020 by 23.8 % compared to the same period of the previous year to 175.6 million EUR
DE000A289VV1
November 23, 2020The sales of HAEMATO AG increased in the first nine months of 2020 by 23.8 % compared to the same period of the previous year to 175.6 million EUR. HAEMATO AG, Berlin (ISIN: DE000A289VV1), achieved IFRS group sales of EUR 59.8 million in the third quarter of 2020 (previous year: EUR 47.8 million). For the observed period from Janu...
HAEMATO AG
About the publication
More HAEMATO AG related information
Type Total Last Made by Go to
Corporate Research 33 15th December 2023 EQS Group AG Corporate Research
Directors Dealings 0 - - DD
Short Seller (DE) 0 - - SSR (DE)
Short Seller (UK) 0 - - SSR (UK)
Disclaimer:

The combination of information with graphic elements makes an important contribution to visual orientation and navigation through complex factual topics. Essential content features can be perceived, grasped and contextually processed much faster. 
The figurative marks, logos and other graphic and textual elements used on this website are for illustrative purposes only. All rights to the aforementioned elements are held by their respective owners. They are used without the intention of copyright infringement or intellectual property infringement.

If you believe that copyrights or intellectual property have been infringed by the choice of illustration, please contact us immediately to clarify the issue.

v.07062023 EN